Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CLRB vs BGMSP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CLRB Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 6–1 Matrix Metrics)

CLRB Overall Winner 6-Pillar Tally: CLRB 3 – 1 BGMSP (2 Tie) Matrix Metrics: CLRB 6 – 1 BGMSP

As of Nov 16, 2026, Cellectar Biosciences INC NEW (CLRB) is the stronger overall head-to-head candidate over BGMSP (BGMSP) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CLRB carries a Unified Composite Score of 39.4/100 (SELL) at $1.04 (N/M Forward P/E, 0.0% operating margin), whereas BGMSP carries 42.7/100 (HOLD) at $1.44 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While BGMSP currently prints a higher short-term Unified Composite Score (42.7/100 HOLD vs. CLRB 39.4/100 SELL), CLRB captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: CLRB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile BGMSP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CLRB vs BGMSP
CLRB NASDAQ Head-to-Head Winner
Cellectar Biosciences INC NEW
Pharmaceutical Preparations
$1.04
-8.77% 1D
Market Cap $11.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.28β · 81% Vol
Unified Composite Score
39.4 / 100 SELL
Tech 25.0 Fund 49.0 Flow 44.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -24.8%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $1.21 · SMA50: $1.60
BGMSP US Equity
BGMSP
Institutional Equity
$1.44
-39.75% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.59β · 201% Vol
Unified Composite Score
42.7 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A

6-Pillar Scorecard Institutional Category Breakdown (CLRB 3 – 1 BGMSP)

Columns: Metric · CLRB · BGMSP
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CLRB
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $11.6M N/A
3. Profitability & Quality CLRB
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -162.6% N/A
4. Balance Sheet & Cash Flow CLRB
Cash Generation (TTM) -$19M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.8M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BGMSP
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CLRB (6) vs BGMSP (1)
Institutional Metric CLRB BGMSP Criterion Row Edge
Market Capitalization
Scale
$11.6M N/A Larger Scale CLRB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth CLRB
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin CLRB
Net Profit Margin
Profitability
0.0% N/A Higher Margin CLRB
Return on Equity (ROE)
Capital Efficiency
-162.6% N/A Higher ROE CLRB
52-Week Range Position
Momentum
0% ($1–$5) 0% ($1–$14) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.28β · 81% Vol 0.59β · 201% Vol Lower Realized Risk CLRB
Unified Institutional Score
Composite Signal
39.4 / 100 (SELL) 42.7 / 100 (HOLD) Higher Composite BGMSP
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$19M ($6.8M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CLRB +69.34 pp
CLRB: +8.36% · BGMSP: -60.98%
3M Horizon CLRB +84.13 pp
CLRB: +11.72% · BGMSP: -72.41%
6M Horizon CLRB +84.13 pp
CLRB: +11.72% · BGMSP: -72.41%
1Y Horizon CLRB +84.13 pp
CLRB: +11.72% · BGMSP: -72.41%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLRB vs BGMSP. Trailing 12-month operating profitability (CLRB 0.0% vs BGMSP N/A) and valuation multiples (CLRB N/M vs BGMSP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CLRB ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-162.6% · N/M
BGMSP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CLRB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLRB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BGMSP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGMSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CLRB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BGMSP Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CLRB vs BGMSP Key Questions & Quantitative Answers

As of Nov 16, 2026, Cellectar Biosciences INC NEW (CLRB) is the stronger overall head-to-head candidate over BGMSP (BGMSP) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CLRB carries a Unified Composite Score of 39.4/100 (SELL) at $1.04 (N/M Forward P/E, 0.0% operating margin), whereas BGMSP carries 42.7/100 (HOLD) at $1.44 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While BGMSP currently prints a higher short-term Unified Composite Score (42.7/100 HOLD vs. CLRB 39.4/100 SELL), CLRB captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: CLRB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile BGMSP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CLRB leads the Growth & Scale pillar: CLRB posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with BGMSP at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, CLRB generates N/A in USD-normalized revenue versus N/A for BGMSP. In operating R&D and SG&A reinvestment, CLRB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BGMSP.

CLRB and BGMSP trade at balanced relative valuation multiples. CLRB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas BGMSP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLRB (-162.6% ROE) versus BGMSP (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, CLRB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.28β · 81% Vol realized risk). By comparison, BGMSP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 201% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.